Continued Deucravacitinib Treatment for Lupus Patients Who Finished Earlier Studies
Continues deucravacitinib for adults with lupus who completed earlier studies.
Plain-language title generated from the registry record
Registry title: A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132
Key facts
- Where
- Farmington, Jackson, New York, and Oklahoma City, United StatesSee the 4 sites
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT06875960, who can take part
Where in United States
- FarmingtonFarmington, United StatesNo longer taking part
- JacksonJackson, United StatesNo longer taking part
- New York University School of MedicineNew York, United StatesTaking people
- Oklahoma Medical Research FoundationOklahoma City, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Bristol-Myers Squibb
- Trial code
- NCT06875960
- Record updated
- 9 September 2026
- Original description
The purpose of this study is to allow the continued administration of Deucravacitinib in participants with Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) who have completed study IM011074 or Study IM011132Read full original descriptionShow less
A Continuation Protocol for Deucravacitinib in Patients With Patients With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132
The purpose of this study is to allow the continued administration of Deucravacitinib in participants with Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) who have completed study IM011074 or Study IM011132
Inclusion: Participants must have completed Study IM011074 or Study IM011132 through the protocol-required treatment period; Participants must be, based on the physician's medical judgement, likely to receive benefit from receiving treatment with deucravacitinib; Participants must have received IP within 60 days of enrollment. Exceptions may be granted based upon consultation with BMS.
Exclusion: Participants must not have any disease or medical condition that, in the opinion of the physician, would make the subject unsuitable for this protocol, would interfere with the interpretation of subject safety or considered unsuitable by the physician for any other reason; Participants must not have any evidence of active Tuberculosis (TB); Other protocol-defined Inclusion/Exclusion criteria apply.